Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water + Ticagrelor OD tablet (90 mg single dose) administered without water + Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube + Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bioavailability
Conditions
Bioavailability, Healthy Subjects
Trial Timeline
Jun 1, 2015 → Jul 1, 2015
NCT ID
NCT02400333About Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water + Ticagrelor OD tablet (90 mg single dose) administered without water + Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube + Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water
Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water + Ticagrelor OD tablet (90 mg single dose) administered without water + Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube + Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water is a phase 1 stage product being developed by AstraZeneca for Bioavailability. The current trial status is completed. This product is registered under clinical trial identifier NCT02400333. Target conditions include Bioavailability, Healthy Subjects.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02400333 | Phase 1 | Completed |
Competing Products
20 competing products in Bioavailability